



Continuation of Substance of Interview including description of the general nature of what was discussed: The compounds were disclosed to have efficacy on page 48 section [00135] which should be incorporated into the claims. An examiner's amendment was authorized to cancel claims 26, 28, 29, 32 amend claim 21 and added new claims 33-35 employing the scope of page 48,.